These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 30599229)
1. Emerging vistas in theranostic medicine. Shetty Y; Prabhu P; Prabhakar B Int J Pharm; 2019 Mar; 558():29-42. PubMed ID: 30599229 [TBL] [Abstract][Full Text] [Related]
2. Theranostic Nanomedicine; A Next Generation Platform for Cancer Diagnosis and Therapy. Sharma R; Mody N; Agrawal U; Vyas SP Mini Rev Med Chem; 2017; 17(18):1746-1757. PubMed ID: 26891932 [TBL] [Abstract][Full Text] [Related]
3. Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine. Moorthy H; Govindaraju T ACS Appl Bio Mater; 2021 Feb; 4(2):1115-1139. PubMed ID: 35014470 [TBL] [Abstract][Full Text] [Related]
4. Theranostic applications of nanoparticles in neurodegenerative disorders. Ramanathan S; Archunan G; Sivakumar M; Tamil Selvan S; Fred AL; Kumar S; Gulyás B; Padmanabhan P Int J Nanomedicine; 2018; 13():5561-5576. PubMed ID: 30271147 [TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Development of Theranostic Nanoparticles for Cardiovascular Diseases. Wu Y; Vazquez-Prada KX; Liu Y; Whittaker AK; Zhang R; Ta HT Nanotheranostics; 2021; 5(4):499-514. PubMed ID: 34367883 [TBL] [Abstract][Full Text] [Related]
6. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789 [TBL] [Abstract][Full Text] [Related]
7. Towards tailored management of malignant brain tumors with nanotheranostics. Aparicio-Blanco J; Torres-Suárez AI Acta Biomater; 2018 Jun; 73():52-63. PubMed ID: 29678675 [TBL] [Abstract][Full Text] [Related]
8. Gadolinium theranostics for the diagnosis and treatment of cancer. Robertson AG; Rendina LM Chem Soc Rev; 2021 Apr; 50(7):4231-4244. PubMed ID: 33599224 [TBL] [Abstract][Full Text] [Related]
9. Disulfide-based multifunctional conjugates for targeted theranostic drug delivery. Lee MH; Sessler JL; Kim JS Acc Chem Res; 2015 Nov; 48(11):2935-46. PubMed ID: 26513450 [TBL] [Abstract][Full Text] [Related]
10. Targeting Oxidative Stress Using Nanoparticles as a Theranostic Strategy for Cardiovascular Diseases. Kim KS; Song CG; Kang PM Antioxid Redox Signal; 2019 Feb; 30(5):733-746. PubMed ID: 29228781 [TBL] [Abstract][Full Text] [Related]
12. Luminescent lanthanide nanomaterials: an emerging tool for theranostic applications. Ranjan S; Jayakumar MK; Zhang Y Nanomedicine (Lond); 2015 May; 10(9):1477-91. PubMed ID: 25996120 [TBL] [Abstract][Full Text] [Related]
13. Theranostic Aspects: Treatment of Cancer by Nanotechnology. Sarkar B; Paira P Mini Rev Med Chem; 2018; 18(11):969-975. PubMed ID: 29189149 [TBL] [Abstract][Full Text] [Related]
14. Theranostic nanoparticles for cancer and cardiovascular applications. Wang D; Lin B; Ai H Pharm Res; 2014 Jun; 31(6):1390-406. PubMed ID: 24595494 [TBL] [Abstract][Full Text] [Related]
15. Theranostic Agents in Musculoskeletal Disorders. Katal S; Maldonado A; Carrascoso J; Assadi M; Gholamrezanezhad A PET Clin; 2021 Jul; 16(3):441-448. PubMed ID: 34053587 [TBL] [Abstract][Full Text] [Related]
16. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine? Blau R; Krivitsky A; Epshtein Y; Satchi-Fainaro R Drug Resist Updat; 2016 Jul; 27():39-58. PubMed ID: 27449597 [TBL] [Abstract][Full Text] [Related]